;PMID: 2318973
;source_file_950.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..97] = [t:43..97]
;2)sentence:[e:98..154] = [t:98..154]
;3)section:[e:158..233] = [t:158..233]
;4)section:[e:237..353] = [t:237..353]
;5)sentence:[e:357..618] = [t:357..618]
;6)sentence:[e:619..812] = [t:619..812]
;7)sentence:[e:813..977] = [t:813..977]
;8)sentence:[e:978..1201] = [t:978..1201]
;9)sentence:[e:1202..1272] = [t:1202..1272]
;10)sentence:[e:1273..1419] = [t:1273..1419]
;11)sentence:[e:1420..1548] = [t:1420..1548]
;12)sentence:[e:1550..1699] = [t:1550..1699]
;13)sentence:[e:1700..1818] = [t:1700..1818]
;14)section:[e:1822..1866] = [t:1822..1866]

;section 0 Span:0..37
;J Clin Invest. 1990 Apr;85(4):1191-8.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..13] Invest) (.:[13..14] .)
        (CD:[15..19] 1990) (CC:[20..27] Apr;85-LRB-) (CD:[27..29] 4-RRB-)
        (CD:[29..34] :1191) (::[34..35] -) (CD:[35..37] 8.)))

;sentence 1 Span:43..97
;Feedback regulation of bile-acid synthesis in the rat.
;[66..75]:substance:"bile-acid"
(SENT
  (NP-HLN
    (NP (NN:[43..51] Feedback) (NN:[52..62] regulation))
    (PP (IN:[63..65] of)
      (NP
        (NML (NN:[66..70] bile) (HYPH:[70..71] -) (NN:[71..75] acid))
        (NN:[76..85] synthesis)))
    (PP-LOC (IN:[86..88] in)
      (NP (DT:[89..92] the) (NN:[93..96] rat)))
    (.:[96..97] .)))

;sentence 2 Span:98..154
;Differing effects of  taurocholate and tauroursocholate.
;[120..132]:substance:"taurocholate"
;[137..153]:substance:"tauroursocholate"
(SENT
  (NP-HLN
    (NP (VBG:[98..107] Differing) (NNS:[108..115] effects))
    (PP (IN:[116..118] of)
      (NP (NN:[120..132] taurocholate) (CC:[133..136] and)
          (NN:[137..153] tauroursocholate)))
    (.:[153..154] .)))

;section 3 Span:158..233
;Shefer S, Nguyen L, Salen G, Batta AK, Brooker D, Zaki FG, Rani I, Tint GS.
(SEC
  (FRAG (NNP:[158..164] Shefer) (NNP:[165..167] S,) (NNP:[168..174] Nguyen)
        (NNP:[175..177] L,) (NNP:[178..183] Salen) (NNP:[184..185] G)
        (,:[185..186] ,) (NNP:[187..192] Batta) (NNP:[193..195] AK)
        (,:[195..196] ,) (NNP:[197..204] Brooker) (NNP:[205..206] D)
        (,:[206..207] ,) (NNP:[208..212] Zaki) (NNP:[213..215] FG)
        (,:[215..216] ,) (NNP:[217..221] Rani) (NNP:[222..223] I)
        (,:[223..224] ,) (NNP:[225..229] Tint) (NNP:[230..232] GS)
        (.:[232..233] .)))

;section 4 Span:237..353
;Department of Medicine, University of Medicine and Dentistry of New
;Jersey-New  Jersey Medical School, Newark 07103.
(SEC
  (FRAG (NNP:[237..247] Department) (IN:[248..250] of) (NNP:[251..259] Medicine)
        (,:[259..260] ,) (NNP:[261..271] University) (IN:[272..274] of)
        (NNP:[275..283] Medicine) (CC:[284..287] and) (DT:[288..297] Dentistry)
        (IN:[298..300] of) (NNP:[301..304] New) (NNP:[305..311] Jersey)
        (HYPH:[311..312] -) (NNP:[312..315] New) (NNP:[317..323] Jersey)
        (NNP:[324..331] Medical) (NNP:[332..338] School) (,:[338..339] ,)
        (NNP:[340..346] Newark) (CD:[347..352] 07103) (.:[352..353] .)))

;sentence 5 Span:357..618
;We studied the effect of the orientation of the 7-hydroxyl group in
;taurocholate  (7 alpha) and tauroursocholate (7 beta) on the feedback
;regulation of bile-acid  synthesis and its rate-controlling enzyme,
;cholesterol 7 alpha-hydroxylase, in  bile-fistula rats.
;[425..437]:substance:"taurocholate"
;[440..447]:substance:"7 alpha"
;[453..469]:substance:"tauroursocholate"
;[471..477]:substance:"7 beta"
;[509..518]:substance:"bile-acid"
;[555..561]:cyp450:"enzyme"
;[563..594]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ (PRP:[357..359] We))
    (VP (VBD:[360..367] studied)
      (NP
        (NP (DT:[368..371] the) (NN:[372..378] effect))
        (PP (IN:[379..381] of)
          (NP
            (NP (DT:[382..385] the) (NN:[386..397] orientation))
            (PP (IN:[398..400] of)
              (NP (DT:[401..404] the) (NN:[405..415] 7-hydroxyl)
                  (NN:[416..421] group)))
            (PP-LOC (IN:[422..424] in)
              (NP
                (NP
                  (NP (NN:[425..437] taurocholate))
                  (NP (-LRB-:[439..440] -LRB-)
                     (CD:[440..441] 7) (SYM:[442..447] alpha)
                    (-RRB-:[447..448] -RRB-)))
                (CC:[449..452] and)
                (NP
                  (NP (NN:[453..469] tauroursocholate))
                  (NP (-LRB-:[470..471] -LRB-)
                     (CD:[471..472] 7) (SYM:[473..477] beta)
                    (-RRB-:[477..478] -RRB-)))))))
        (PP (IN:[479..481] on)
          (NP
            (NP (DT:[482..485] the) (NN:[486..494] feedback)
                (NN:[495..505] regulation))
            (PP (IN:[506..508] of)
              (NP
                (NP
                  (NML (NN:[509..513] bile) (HYPH:[513..514] -)
                       (NN:[514..518] acid))
                  (NN:[520..529] synthesis))
                (CC:[530..533] and)
                (NP
                  (NP (PRP$:[534..537] its)
                    (ADJP (NN:[538..542] rate) (HYPH:[542..543] -)
                          (VBG:[543..554] controlling))
                    (NN:[555..561] enzyme))
                  (,:[561..562] ,)
                  (NP (NN:[563..574] cholesterol) (CD:[575..576] 7)
                      (NN:[577..594] alpha-hydroxylase))))))))
      (,:[594..595] ,)
      (PP-LOC (IN:[596..598] in)
        (NP
          (NML (NN:[600..604] bile) (HYPH:[604..605] -) (NN:[605..612] fistula))
          (NNS:[613..617] rats))))
    (.:[617..618] .)))

;sentence 6 Span:619..812
;To ensure a constant supply of cholesterol and to label newly  synthesized
;bile acids, RS[2-14C]mevalonolactone was infused intraduodenally at  154
;mumol/h before and during bile-acid infusion.
;[650..661]:substance:"cholesterol"
;[694..704]:substance:"bile acids"
;[706..730]:substance:"RS[2-14C]mevalonolactone"
;[763..766]:quantitative-value:"154"
;[767..774]:quantitative-units:"mumol/h"
;[793..802]:substance:"bile-acid"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[619..619] *))
      (VP
        (VP (TO:[619..621] To)
          (VP (VB:[622..628] ensure)
            (NP
              (NP (DT:[629..630] a) (JJ:[631..639] constant)
                  (NN:[640..646] supply))
              (PP (IN:[647..649] of)
                (NP (NN:[650..661] cholesterol))))))
        (CC:[662..665] and)
        (VP (TO:[666..668] to)
          (VP (VB:[669..674] label)
            (NP
              (ADJP (RB:[675..680] newly) (VBN:[682..693] synthesized))
               (NN:[694..698] bile) (NNS:[699..704] acids))))))
    (,:[704..705] ,)
    (NP-SBJ-2 (NN:[706..730] RS-LSB-2-14C-RSB-mevalonolactone))
    (VP (VBD:[731..734] was)
      (VP (VBN:[735..742] infused)
        (NP-2 (-NONE-:[742..742] *))
        (ADVP-MNR (RB:[743..758] intraduodenally))
        (PP (IN:[759..761] at)
          (NP
            (NP (CD:[763..766] 154) (NN:[767..772] mumol))
            (PP (SYM:[772..773] /)
              (NP (NN:[773..774] h)))))
        (PP-TMP (IN:[775..781] before) (CC:[782..785] and)
                (IN:[786..792] during)
          (NP
            (NML (NN:[793..797] bile) (HYPH:[797..798] -) (NN:[798..802] acid))
            (NN:[803..811] infusion)))))
    (.:[811..812] .)))

;sentence 7 Span:813..977
;Mevalonolactone inhibited  hydroxymethyl-glutaryl CoA reductase activity 90%
;but did not increase bile-acid  synthesis and cholesterol 7 alpha-hydroxylase
;activity.
;[813..828]:substance:"Mevalonolactone"
;[840..876]:substance:"hydroxymethyl-glutaryl CoA reductase"
;[886..889]:quantitative-value:"90%"
;[911..920]:substance:"bile-acid"
;[936..967]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ (NN:[813..828] Mevalonolactone))
    (VP
      (VP (VBD:[829..838] inhibited)
        (NP
          (NML
            (NML (NN:[840..862] hydroxymethyl-glutaryl) (NN:[863..866] CoA))
            (NN:[867..876] reductase))
          (NN:[877..885] activity))
        (NP-EXT (CD:[886..888] 90) (NN:[888..889] %)))
      (CC:[890..893] but)
      (VP (VBD:[894..897] did) (RB:[898..901] not)
        (VP (VB:[902..910] increase)
          (NP
            (NP
              (NML (NN:[911..915] bile) (HYPH:[915..916] -) (NN:[916..920] acid))
              (NN:[922..931] synthesis))
            (CC:[932..935] and)
            (NP
              (NML (NN:[936..947] cholesterol) (CD:[948..949] 7)
                   (NN:[950..967] alpha-hydroxylase))
              (NN:[968..976] activity))))))
    (.:[976..977] .)))

;sentence 8 Span:978..1201
;When sodium taurocholate  was infused at the rate of 27 mumol/100 g rat per h
;(equivalent to the hourly  hepatic bile-acid flux), bile-acid synthesis
;decreased 82% and cholesterol 7  alpha-hydroxylase activity declined 78%.
;[983..1002]:substance:"sodium taurocholate"
;[1031..1033]:quantitative-value:"27"
;[1034..1055]:quantitative-units:"mumol/100 g rat per h"
;[1091..1100]:substance:"bile-acid"
;[1108..1117]:substance:"bile-acid"
;[1138..1141]:quantitative-value:"82%"
;[1146..1178]:cyp450:"cholesterol 7  alpha-hydroxylase"
;[1197..1200]:quantitative-value:"78%"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-2 (WRB:[978..982] When))
      (S
        (NP-SBJ-1 (NN:[983..989] sodium) (NN:[990..1002] taurocholate))
        (VP (VBD:[1004..1007] was)
          (VP (VBN:[1008..1015] infused)
            (NP-1 (-NONE-:[1015..1015] *))
            (PP (IN:[1016..1018] at)
              (NP
                (NP (DT:[1019..1022] the) (NN:[1023..1027] rate))
                (PP (IN:[1028..1030] of)
                  (NP
                    (NP (CD:[1031..1033] 27) (NN:[1034..1039] mumol))
                    (PP (SYM:[1039..1040] /)
                      (NP
                        (NP (CD:[1040..1043] 100) (NN:[1044..1045] g))
                        (NP (NN:[1046..1049] rat))))
                    (PP (IN:[1050..1053] per)
                      (NP (NN:[1054..1055] h)))))
                (PRN (-LRB-:[1056..1057] -LRB-)
                  (ADJP (JJ:[1057..1067] equivalent)
                    (PP (TO:[1068..1070] to)
                      (NP (DT:[1071..1074] the) (JJ:[1075..1081] hourly)
                          (JJ:[1083..1090] hepatic)
                        (NML (NN:[1091..1095] bile) (HYPH:[1095..1096] -)
                             (NN:[1096..1100] acid))
                        (NN:[1101..1105] flux))))
                  (-RRB-:[1105..1106] -RRB-))))
            (ADVP-TMP-2 (-NONE-:[1106..1106] *T*))))))
    (,:[1106..1107] ,)
    (S
      (NP-SBJ
        (NML (NN:[1108..1112] bile) (HYPH:[1112..1113] -) (NN:[1113..1117] acid))
        (NN:[1118..1127] synthesis))
      (VP (VBD:[1128..1137] decreased)
        (NP-EXT (CD:[1138..1140] 82) (NN:[1140..1141] %))))
    (CC:[1142..1145] and)
    (S
      (NP-SBJ
        (NML (NN:[1146..1157] cholesterol) (CD:[1158..1159] 7)
             (NN:[1161..1178] alpha-hydroxylase))
        (NN:[1179..1187] activity))
      (VP (VBD:[1188..1196] declined)
        (NP-EXT (CD:[1197..1199] 78) (NN:[1199..1200] %))))
    (.:[1200..1201] .)))

;sentence 9 Span:1202..1272
;This inhibitory effect was observed in  the absence of hepatic damage.
(SENT
  (S
    (NP-SBJ-1 (DT:[1202..1206] This) (JJ:[1207..1217] inhibitory)
              (NN:[1218..1224] effect))
    (VP (VBD:[1225..1228] was)
      (VP (VBN:[1229..1237] observed)
        (NP-1 (-NONE-:[1237..1237] *))
        (PP (IN:[1238..1240] in)
          (NP
            (NP (DT:[1242..1245] the) (NN:[1246..1253] absence))
            (PP (IN:[1254..1256] of)
              (NP (JJ:[1257..1264] hepatic) (NN:[1265..1271] damage)))))))
    (.:[1271..1272] .)))

;sentence 10 Span:1273..1419
;In contrast, sodium tauroursocholate infused at  the same rate did not
;decrease bile-acid synthesis nor cholesterol 7  alpha-hydroxylase activity.
;[1286..1309]:substance:"sodium tauroursocholate"
;[1353..1362]:substance:"bile-acid"
;[1377..1409]:cyp450:"cholesterol 7  alpha-hydroxylase"
(SENT
  (S
    (PP (IN:[1273..1275] In)
      (NP (NN:[1276..1284] contrast)))
    (,:[1284..1285] ,)
    (NP-SBJ
      (NP (NN:[1286..1292] sodium) (NN:[1293..1309] tauroursocholate))
      (VP (VBN:[1310..1317] infused)
        (NP (-NONE-:[1317..1317] *))
        (PP (IN:[1318..1320] at)
          (NP (DT:[1322..1325] the) (JJ:[1326..1330] same)
              (NN:[1331..1335] rate)))))
    (VP (VBD:[1336..1339] did) (RB:[1340..1343] not)
      (VP (VB:[1344..1352] decrease)
        (NP
          (NP
            (NML (NN:[1353..1357] bile) (HYPH:[1357..1358] -)
                 (NN:[1358..1362] acid))
            (NN:[1363..1372] synthesis))
          (CC:[1373..1376] nor)
          (NP
            (NML (NN:[1377..1388] cholesterol) (CD:[1389..1390] 7)
                 (NN:[1392..1409] alpha-hydroxylase))
            (NN:[1410..1418] activity)))))
    (.:[1418..1419] .)))

;sentence 11 Span:1420..1548
;Hepatic cholesterol content rose 36% with sodium  taurocholate but did not
;change during sodium tauroursocholate administration.
;[1428..1439]:substance:"cholesterol"
;[1453..1456]:quantitative-value:"36%"
;[1462..1482]:substance:"sodium  taurocholate"
;[1509..1532]:substance:"sodium tauroursocholate"
(SENT
  (S
    (NP-SBJ (JJ:[1420..1427] Hepatic) (NN:[1428..1439] cholesterol)
            (NN:[1440..1447] content))
    (VP
      (VP (VBD:[1448..1452] rose)
        (NP-EXT (CD:[1453..1455] 36) (NN:[1455..1456] %))
        (PP (IN:[1457..1461] with)
          (NP (NN:[1462..1468] sodium) (NN:[1470..1482] taurocholate))))
      (CC:[1483..1486] but)
      (VP (VBD:[1487..1490] did) (RB:[1491..1494] not)
        (VP (VB:[1495..1501] change)
          (PP-TMP (IN:[1502..1508] during)
            (NP
              (NML (NN:[1509..1515] sodium) (NN:[1516..1532] tauroursocholate))
              (NN:[1533..1547] administration))))))
    (.:[1547..1548] .)))

;sentence 12 Span:1550..1699
;These results demonstrate that the feedback inhibition of bile-acid synthesis
;is  mediated through the regulation of cholesterol 7 alpha-hydroxylase.
;[1608..1617]:substance:"bile-acid"
;[1667..1698]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ (DT:[1550..1555] These) (NNS:[1556..1563] results))
    (VP (VBP:[1564..1575] demonstrate)
      (SBAR (IN:[1576..1580] that)
        (S
          (NP-SBJ-1
            (NP (DT:[1581..1584] the) (NN:[1585..1593] feedback)
                (NN:[1594..1604] inhibition))
            (PP (IN:[1605..1607] of)
              (NP
                (NML (NN:[1608..1612] bile) (HYPH:[1612..1613] -)
                     (NN:[1613..1617] acid))
                (NN:[1618..1627] synthesis))))
          (VP (VBZ:[1628..1630] is)
            (VP (VBN:[1632..1640] mediated)
              (NP-1 (-NONE-:[1640..1640] *))
              (PP (IN:[1641..1648] through)
                (NP
                  (NP (DT:[1649..1652] the) (NN:[1653..1663] regulation))
                  (PP (IN:[1664..1666] of)
                    (NP (NN:[1667..1678] cholesterol) (CD:[1679..1680] 7)
                        (NN:[1681..1698] alpha-hydroxylase))))))))))
    (.:[1698..1699] .)))

;sentence 13 Span:1700..1818
;In these  experiments, taurocholate was a far more potent inhibitor than its
;7  beta-hydroxy epimer, tauroursocholate.
;[1723..1735]:substance:"taurocholate"
;[1758..1767]:substance:"inhibitor"
;[1777..1799]:substance:"7  beta-hydroxy epimer"
;[1801..1817]:substance:"tauroursocholate"
(SENT
  (S
    (PP-LOC (IN:[1700..1702] In)
      (NP (DT:[1703..1708] these) (NNS:[1710..1721] experiments)))
    (,:[1721..1722] ,)
    (NP-SBJ (NN:[1723..1735] taurocholate))
    (VP (VBD:[1736..1739] was)
      (NP-PRD
        (NP (DT:[1740..1741] a)
          (ADJP (RB:[1742..1745] far) (RBR:[1746..1750] more)
                (JJ:[1751..1757] potent))
          (NN:[1758..1767] inhibitor))
        (PP (IN:[1768..1772] than)
          (NP
            (NP (PRP$:[1773..1776] its)
              
              (NML (CD:[1777..1778] 7) (NN:[1780..1792] beta-hydroxy))
              (NN:[1793..1799] epimer))
            (,:[1799..1800] ,)
            (NP (NN:[1801..1817] tauroursocholate))))))
    (.:[1817..1818] .)))

;section 14 Span:1822..1866
;PMID: 2318973 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1822..1826] PMID) (::[1826..1827] :) (CD:[1828..1835] 2318973)
        (NN:[1836..1837] -LSB-) (NNP:[1837..1843] PubMed) (::[1844..1845] -)
        (NN:[1846..1853] indexed) (IN:[1854..1857] for)
        (NNP:[1858..1866] MEDLINE-RSB-)))
